D-dimer, a degradation product of cross-linked fibrin formed during activation of the coagulation system, is commonly used to exclude thromboembolic disease in outpatients suspected of having deep venous thrombosis (DVT) and pulmonaryembolism (PE). DVT and PE is relatively common and can cause sudden, fatal embolic events in the pulmonary arteries and other regions. Measurement of the D-Dimer level in plasma has been used as a screening strategy for subclinical DVT. A systematic review reported that a normal range of a highly sensitive D-dimer level accurately ruled out DVT in patients classified as having a low or moderate clinical probability of DVT. The DVT is a high-risk factor for the stroke because of advanced age, hemiplegia, and coagulation disorders, and DVT can cause paradoxical embolic stroke via a right-to left shunt. Thus, it is important to monitor the level of D-Dimer the incidence and characteristics of DVT in acute stroke patients. The Plasma D-dimer level has proven to be useful for DVT screening in chronic stroke patients undergoing rehabilitation. National and international scientific organizations have suggested the use of these markers when implementing new diagnostic strategies in patients with coronary syndrome. Since D-Dimer is well known to be an important prognostic indicator of heart diseases, its most definitive role is on monitoring post-treatment clinical status and the post therapeutic evaluation of Patients